Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $45.97 USD
Change Today -0.11 / -0.24%
Volume 96.6K
HPTX On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 8:10 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

hyperion therapeutics inc (HPTX) Snapshot

Open
$46.05
Previous Close
$46.08
Day High
$46.09
Day Low
$45.96
52 Week High
03/30/15 - $46.96
52 Week Low
12/1/14 - $20.23
Market Cap
955.0M
Average Volume 10 Days
317.4K
EPS TTM
$0.58
Shares Outstanding
20.8M
EX-Date
--
P/E TM
78.7x
Dividend
--
Dividend Yield
--
Current Stock Chart for HYPERION THERAPEUTICS INC (HPTX)

hyperion therapeutics inc (HPTX) Related Bloomberg News

View More Bloomberg News

hyperion therapeutics inc (HPTX) Related Businessweek News

No Related Businessweek News Found

hyperion therapeutics inc (HPTX) Details

Hyperion Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat orphan diseases in the United states, Canada, and internationally. The company offers RAVICTI used as a nitrogen-binding agent for chronic management of urea cycle disorder (UCD) in adult and pediatric patients; and BUPHENYL and AMMONAPS therapy for treatment of three UCD subtypes. It is also developing glycerol phenylbutyrate, an active pharmaceutical ingredient in RAVICTI to treat hepatic encephalopathy. The company was founded in 2006 and is headquartered in Brisbane, California.

80 Employees
Last Reported Date: 03/4/15
Founded in 2006

hyperion therapeutics inc (HPTX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $575.0K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $347.0K
Chief Medical Officer
Total Annual Compensation: $375.0K
Chief Commercial Officer and Senior Vice Pres...
Total Annual Compensation: $347.0K
Chief Legal Officer, Senior Vice President of...
Total Annual Compensation: $195.9K
Compensation as of Fiscal Year 2013.

hyperion therapeutics inc (HPTX) Key Developments

Horizon Pharma plc, Hyperion Therapeutics, Inc. - M&A Call

To review definitive agreement under which Horizon Pharma will acquire all of the issued and outstanding shares of Hyperion's common stock for $46.00 per share in cash or approximately $1.1 billion on a fully diluted basis and related matters

Hyperion Therapeutics, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Revenues Guidance for the Year 2015

Hyperion Therapeutics, Inc. reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported total revenues of $30,806,000 against $18,627,000 a year ago. Income from operations was $6,729,000 against $879,000 last year. Income before income taxes was $6,395,000 against $517,000 last year. Net income was $7,099,000 or $0.32 per diluted share against $468,000 or $0.02 per basic and diluted share last year. Adjusted net income was $10,309,000 or $0.47 per diluted share against $4,067,000 or $0.19 per diluted share last year. For the full year, the company reported total revenues of $113,584,000 against $42,204,000 a year ago. Loss from operations was $4,207,000 against $13,417,000 last year. Loss before income taxes was $5,952,000 against income before income taxes of $16,676,000 last year. Net loss was $6,255,000 or $0.31 per basic and diluted share against net income of $16,627,000 or $0.80 per diluted share last year. Adjusted net income was $36,210,000 or $1.67 per diluted share against adjusted net loss of $5,463,000 or $0.28 per basic and diluted share last year. The company provided revenues guidance for the year 2015. The company expects total net revenues to be in the range of $120 million to $128 million, net of co-payment assistance.

Hyperion Therapeutics, Inc. to Report Q4, 2014 Results on Feb 26, 2015

Hyperion Therapeutics, Inc. announced that they will report Q4, 2014 results at 4:30 PM, US Eastern Standard Time on Feb 26, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HPTX:US $45.97 USD -0.11

HPTX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for HPTX.
View Industry Companies
 

Industry Analysis

HPTX

Industry Average

Valuation HPTX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 8.4x
Price/Book 7.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 7.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HYPERION THERAPEUTICS INC, please visit www.hyperiontx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.